Lexicon Pharmaceuticals Inc. [NASDAQ: LXRX] loss -4.96% or -0.07 points to close at $1.34 with a heavy trading volume of 3095278 shares. The company report on September 7, 2023 at 4:30 PM that Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference.
Jeffrey L. Wade, Lexicon’s president and chief financial officer, will make a company presentation at 5:00 pm ET on Tuesday, September 12th.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
It opened the trading session at $1.38, the shares rose to $1.41 and dropped to $1.275, the range by which the price of stock traded the whole day. The daily chart for LXRX points out that the company has recorded -41.48% loss over the past six months. However, it is still 4.29% higher than its most recent low trading price.
If we look at the average trading volume of 1.77M shares, LXRX reached to a volume of 3095278 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Lexicon Pharmaceuticals Inc. [LXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $5.77 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Lexicon Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on March 07, 2023.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc. is set at 0.10, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 836.03. The Price to Book ratio for the last quarter was 1.47, with the Price to Cash per share for the same quarter was set at 1.03.
Trading performance analysis for LXRX stock
Lexicon Pharmaceuticals Inc. [LXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.28. With this latest performance, LXRX shares dropped by -17.79% in over the last four-week period, additionally sinking by -41.48% over the last 6 months – not to mention a drop of -51.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 23.19, with the RSI for the last a single of trading hit 15.82, and the three-weeks RSI is set at 28.51 for Lexicon Pharmaceuticals Inc. [LXRX]. The present Moving Average for the last 50 days of trading for this stock 1.8628, while it was recorded at 1.4760 for the last single week of trading, and 2.2673 for the last 200 days.
Lexicon Pharmaceuticals Inc. [LXRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc. [LXRX] shares currently have an operating margin of -72489.21 and a Gross Margin at -207.19. Lexicon Pharmaceuticals Inc.’s Net Margin is presently recorded at -73341.01.
Return on Total Capital for LXRX is now -69.90, given the latest momentum, and Return on Invested Capital for the company is -71.31. Return on Equity for this stock declined to -88.37, with Return on Assets sitting at -61.56. When it comes to the capital structure of this company, Lexicon Pharmaceuticals Inc. [LXRX] has a Total Debt to Total Equity ratio set at 47.21. Additionally, LXRX Total Debt to Total Capital is recorded at 32.07, with Total Debt to Total Assets ending up at 28.46. Long-Term Debt to Equity for the company is recorded at 46.11, with the Long-Term Debt to Total Capital now at 31.32.
Reflecting on the efficiency of the workforce at the company, Lexicon Pharmaceuticals Inc. [LXRX] managed to generate an average of -$755,141 per employee. Receivables Turnover for the company is 6.62 with a Total Asset Turnover recorded at a value of 0.00.Lexicon Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.10 and a Current Ratio set at 10.10.
An analysis of Institutional ownership at Lexicon Pharmaceuticals Inc. [LXRX]
The top three institutional holders of LXRX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in LXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in LXRX stock with ownership which is approximately 5.7381%.
